Gsk (GLAXF) Shares Outstanding (Weighted Average) (2016 - 2025)
Gsk has reported Shares Outstanding (Weighted Average) over the past 11 years, most recently at $5.4 billion for Q4 2025.
- Quarterly results put Shares Outstanding (Weighted Average) at $5.4 billion for Q4 2025, up 2.97% from a year ago — trailing twelve months through Dec 2025 was $5.4 billion (up 2.97% YoY), and the annual figure for FY2025 was $5.4 billion, up 2.97%.
- Shares Outstanding (Weighted Average) for Q4 2025 was $5.4 billion at Gsk, up from $5.2 billion in the prior quarter.
- Over the last five years, Shares Outstanding (Weighted Average) for GLAXF hit a ceiling of $5.4 billion in Q4 2021 and a floor of $4.7 billion in Q4 2022.
- Median Shares Outstanding (Weighted Average) over the past 5 years was $5.2 billion (2024), compared with a mean of $5.2 billion.
- Biggest five-year swings in Shares Outstanding (Weighted Average): dropped 12.49% in 2022 and later rose 6.5% in 2023.
- Gsk's Shares Outstanding (Weighted Average) stood at $5.4 billion in 2021, then fell by 12.49% to $4.7 billion in 2022, then rose by 6.5% to $5.0 billion in 2023, then rose by 4.05% to $5.2 billion in 2024, then rose by 2.97% to $5.4 billion in 2025.
- The last three reported values for Shares Outstanding (Weighted Average) were $5.4 billion (Q4 2025), $5.2 billion (Q4 2024), and $5.0 billion (Q4 2023) per Business Quant data.